Wall Street Executive and Investor Thomas Janes Joins Vestiage Advisory Committee
Newport Beach, CA (PRWEB) November 12, 2013 -- Vestiage Inc., the science-based anti-aging company, announced today that Thomas Janes of Kerry Capital Advisors and formerly of Bain Capital, Lazard, and Drexel Burnham has joined the Vestiage Advisory Committee. Janes has served on boards of public companies and is a specialist in providing financial strategy and solutions to corporations.
Scott Kimball stated, "Tom has proven to be a valuable resource to us as we continue to grow. We are grateful for the advice and guidance he's given us and are pleased that he has accepted our invitation to join our Advisory Committee."
Janes joins a powerful, select group of key individuals across multiple disciplines that CEO and Founder Scott Kimball has formed over the past several years, drawing upon relationships he has build for 30+ years.
Kimball stated, "The Advisory Committee is now made up of 12 individuals with expertise in finance, consumer products, venture capital, natural products distribution and sales, mergers and acquisitions, public company governance, life sciences, cardiology and anti-aging medicine, aesthetic medicine, athletic performance, consumer product design and packaging, and sports and celebrity marketing. This is an amazing and formidable team. I am grateful to every one of our members. They joined Vestiage because of our principles and what we stand for and because our vision as a Company is very big, but also achievable and realistic. In the end, no matter how successful or reknowned you are in your field, you want to be a part of creating something great and good."
About Vestiage, Inc.
Vestiage (stock symbol "VEST") is a publicly traded anti-aging lifestyle company offering premium branded science-based cosmeceuticals and nutraceuticals. Vestiage is focused on the use of human stem cell, marine/ocean, and cutting edge botanically based science and ingredients to produce highly potent, elegantly formulated products with clinically proven ingredients. Using high potency and novel ingredient combinations, Vestiage creates and distributes cosmeceuticals such as Reluma (http://www.RelumaSkinCare.com) and multifunctional nutraceuticals through RegiMEN supplements and Monterey Bay Nutraceuticals (http://www.MontereyBayNutra.com). Vestiage brands address the top “in demand” anti-aging concerns of men and women. Vestiage research is focused on longevity and human performance science that covers both the cognitive and physical realms. As clinical results validate discoveries, Vestiage intends to apply new potential ingredients or ingredient formulations and combinations to its anti-aging products across brands. To learn more, visit the Company website, http://www.VestiageInc.com.
This Press Release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 with respect to our financial condition, results of operations and business. These forwardlooking statements can be identified by the use of terms such as "believe," "expects," "plan," "intend," "may," "will," "should," "can," or "anticipates," or the negative thereof, or variations thereon, or comparable terminology, or by discussions of strategy. These statements involve known and unknown risks, uncertainties and other factors that may cause industry trends or our actual results to be materially different from any future results expressed or implied by these statements. Important factors that may cause our results to differ from these forward-looking statements include, but are not limited to: (i) changes in or new government regulations or increased enforcement of the same, (ii) unavailability of desirable acquisitions or inability to complete them, (iii) increased costs, including from increased raw material or energy prices, (iv) changes in general worldwide economic or political conditions, (v) adverse publicity or negative consumer perception regarding nutritional supplements, anti-aging or stem cell facial care products or stem cell technology in general, (vi) issues with obtaining raw materials of adequate quality or quantity, (vii) litigation and claims, including product liability, intellectual property and other types, (viii) disruptions from or following acquisitions including the loss of customers, (ix) increased competition, (x) slow or negative growth in the anti-aging or cosmetics, beauty, or nutritional supplement industry or the healthy foods or anti-aging channel, (xi) the loss of key personnel or the inability to manage our operations efficiently, (xii) problems with information management systems, manufacturing efficiencies and operations, (xiii) insurance coverage issues, (xiv) the volatility of the stock market generally and of our stock specifically, (xv) increases in the cost of borrowings or unavailability of additional debt or equity capital, or both, or fluctuations in foreign currencies, and (xvi) interruption of business or negative impact on sales and earnings due to acts of God, acts of war, terrorism, bio-terrorism, civil unrest and other factors outside of our control.
Garrett Heiser, Vestiage, Inc, http://www.vestiageinc.com, 949-258-4404, [email protected]
Share this article